Clinical Trials Logo

Female Breast Carcinoma clinical trials

View clinical trials related to Female Breast Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04290585 Completed - Healthy Subject Clinical Trials

Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography

Start date: March 5, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well technology and health communication works in improving health outcomes in patients scheduled for mammography screening. The Mobile Mammography Screening Program provides a vital health service and it is important that all women scheduled for an appointment show-up to be screened. Technology and health communication may help decrease no-show rates among patients scheduled for mammography screening.

NCT ID: NCT02005770 Completed - Clinical trials for Female Breast Carcinoma

Anesthesia and Circulating Tumor Cells in Breast Cancer

Start date: March 2014
Phase: Phase 4
Study type: Interventional

Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.

NCT ID: NCT01643148 Completed - Clinical trials for Female Breast Carcinoma

The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer

leptin
Start date: January 2011
Phase: N/A
Study type: Observational

Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer. Patients: Consecutive patients aged between 40 - 60 years, with breast disease and informed consent. Interventions: Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay. Hypothesis: Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.